Accessibility Menu
NovaBridge Biosciences logo

NovaBridge Biosciences(NASDAQ) NBP

Market Cap$189.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-87%
5 Year-98%
1 Year-19%
1 Month-16%
$1.61
-1.83%
-0.03Today
After hours$1.61+$0.00 (+0.00%)
NovaBridge Biosciences last closing stock price
MetricPriceDate
Last closeUSD 1.642026-07-30
NovaBridge Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.34%USD 1.772026-07-23
1 month-15.9%USD 1.952026-06-30
3 month-31.09%USD 2.382026-05-01
Year to date-58.79%USD 3.982025-12-31
1 year-19.21%USD 2.032025-07-30
3 year-43.06%USD 2.882023-07-31
5 year-97.9%USD 78.082021-07-30
Since inception-86.88%USD 12.502020-01-17

NovaBridge Biosciences Financials at a Glance

Market Cap

$189.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$19.88M

EPS (TTM)

-$0.44

P/E Ratio

-3.71

Dividend

$0.00

Beta (Volatility)

1.31 (Average)

Price

$1.61

Volume

167,640.882

Open

$1.65

Previous Close

$1.64

Daily Range

$1.58 - $1.65

52-Week Range

$1.46 - $6.79

Estimated Earnings Date

Jul 30, 2026

NBP News

GettyImages-647334054

AbbVie Partners With I-Mab for Cancer Drug

Jim CrumlySep 4, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NovaBridge Biosciences

I-Mab is a biopharmaceutical company focused on the discovery, advancement, and commercialization of biologic therapies. The company aims to address critical medical needs in oncology and autoimmune diseases through a robust pipeline of drug candidates.

Products and Services
  • Eftansomatropin alfa, a long-acting human growth hormone for pediatric growth hormone deficiency
  • Lemzoparlimab, a CD47 monoclonal antibody in Phase 2 clinical evaluation
  • Felzartamab, a CD38 antibody for membranous nephropathy in Phase 1b/2a development
Growth Outlook
  • Strong pipeline with multiple candidates in advanced clinical stages
  • Strategic partnerships with industry leaders like AbbVie and Roche
  • Focus on addressing unmet medical needs in oncology and autoimmune diseases
Financial Highlights
  • Cash and short-term investments totaled $165.6 million as of June 30, 2025
  • Operating expenses reached $992,047 in Q2 2025, reflecting ongoing R&D investments
  • Net income for Q2 2025 was reported at -$767,532, indicating continued investment in growth
I-Mab's commitment to developing innovative therapies is evident in its extensive pipeline, which includes several candidates nearing commercialization. The company has established strategic alliances that enhance its research capabilities and market reach. Financially, I-Mab maintains a strong cash position, allowing for sustained investment in research and development. The focus on addressing significant medical needs positions the company favorably within the biotechnology sector.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

30

CEO

Xi-Yong Fu, PhD, MBA

Website

www.i-mabbiopharma.com

Headquarters

Rockville, MD 20850, US

NBP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-0.59%

Return on Capital

-40.28%

Return on Assets

-53.39%

Earnings Yield

-26.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$189.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

115.38M

Volume

167.64K

Avg. Volume

701.47K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$31.79M

EBITDA

-$31.54M

Operating Cash Flow

-$1.45M

Capital Expenditure

$41.00

Free Cash Flow

-$1.45M

Cash & ST Invst.

$30.14M

Total Debt

$438.46K

NovaBridge Biosciences Performance Analysis

NovaBridge Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD -32,903,536N/A
20232023-12-31USD 631,451N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
NovaBridge Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
NovaBridge Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.51-5.2%
20232023-12-31USD -2.49-44.7%
20242024-12-31USD -0.70-72.0%
20252025-12-31USD -0.48-30.5%
NovaBridge Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-150.0%
Q22025-06-3075.5%
Q32025-09-30-130.3%
Q42025-12-3143.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$189.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.31M

N/A

Employees

30

N/A

Net Income

-$4.40M

+51.4%

EBITDA

-$10.39M

+89.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$30.14M

-97.6%

Total Debt

$438.46K

-98.5%

Accounts Receivable

$256.33K

N/A

Inventory

$0.00

N/A

Long Term Debt

$311.08K

-98.6%

Short Term Debt

$127.38K

-97.9%

Return on Assets

-53.39%

N/A

Return on Invested Capital

-95.18%

N/A

Free Cash Flow

-$14.60M

N/A

Operating Cash Flow

-$14.60M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GALTGalectin Therapeutics Inc.
$2.97-8.05%
ALTAltimmune, Inc.
$2.84-4.70%
ENGNenGene Holdings Inc.
$1.79+1.70%
RCKTRocket Pharmaceuticals, Inc.
$3.11-3.12%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About NBP

What is the current price of NovaBridge Biosciences?

NovaBridge Biosciences is trading at $1.60 per share.

What is the 52-week range for NovaBridge Biosciences?

Over the past 52 weeks, NovaBridge Biosciences has traded between $1.46 and $6.79.

How much debt does NovaBridge Biosciences have?

As of the most recent reporting period, NovaBridge Biosciences reported total debt of $3.07M.

How much cash does NovaBridge Biosciences have on hand?

NovaBridge Biosciences reported $210.63M in cash and cash equivalents in its most recent financial results.

What is NovaBridge Biosciences’s dividend yield?

NovaBridge Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services